Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2016

View Archived Issues

Yisheng Biopharma to collaborate with The Scripps Research Institute in developing new AIDS vaccine

Novel benzoselenazole derivatives as PET tracers for non-invasive assessment of Abeta plaques

S100A8/A9 is a potent serum and molecular imaging biomarker in seronegative arthritis

Ocular Therapeutix reports positive results for phase III trial of Dextenza

Capsazepine improves impaired lung mechanics during endotoxemia

FDA grants orphan and fast track designations to ARMO BioSciences' AM-0010

FDA transfers EUA for ReEBOV Ebola Antigen Rapid Test to Zalgen

Pfizer enters CRADA with NCI to evaluate three immunotherapy agents

EMA's CHMP recommends granting marketing authorization to Afstyla

OpGen collaborates with Merck & Co. on rapid diagnostics to tackle antibiotic resistance

Genfit initiates pediatric program for elafibranor in NAFLD/NASH

Texas A&M University patents antimycobacterial agents

Repros reports promising topline data from phase II studies of Proellex for uterine fibroids

Katholieke Universiteit Leuven discloses PMDT nucleoside phosphonates

FDA issues complete response letter for Heplisav-B BLA

Xiamen University describes ALK and/or c-Met inhibitors

Novartis develops FXR agonists

FDA awards orphan drug designation to ECCS-50 for scleroderma

Vallaurix presents MC1 receptor agonists

Seizure-induced glial activation in the hippocampus suppressed by the novel NAAA inhibitor ARN-16186

Novel delta opioid receptor agonist NC-2800 shows high anxiolytic and antidepressant activity

ERYTECH Pharma withdraws Graspa MAA in Europe

Reata Pharmaceuticals announces plans to study bardoxolone methyl in new indication

Sanofi Genzyme opts in to expand rights to codevelop, co-commercialize Alnylam's fitusiran

Pantoprazole decreases phlebotomy need in HFE-related hemochromatosis

Acticor Biotech and Mediolanum Farmaceutici enter agreement regarding ACT-017 for stroke

CHMP supports approval of AbbVie's Humira for adolescents with hidradenitis suppurativa

Midostaurin NDA granted priority review by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...